OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations

September 12th 2023

Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.

Dr Leal on a PD-L1 Subgroup Analysis of the LUNAR Trial in mNSCLC

September 12th 2023

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

Dr Negrao on JDQ443 Plus TNO155 in Advanced, KRAS G12C–Mutated Solid Tumors

September 11th 2023

Marcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.

Dr Gadgeel on Adagrasib Monotherapy in KRAS G12C–Mutated NSCLC

September 11th 2023

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

Dr Seymour on the Curative Potential for FCR Treatment in CLL

September 11th 2023

John Seymour, MBBS, FRACP, PhD, discusses the curative potential of fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia.

Dr Miranda-Galvis on the Investigation of Social Determinants of Health in Hematologic Malignancies

September 11th 2023

Marisol Miranda-Galvis, DDS, MS, PhD, discusses the investigation of disparities in survival outcomes of patients with hematologic malignancies relating to social determinants.

Dr Hunter on the Current Treatment Landscape of JAK Inhibitor Treatment in Myelofibrosis

September 11th 2023

Anthony M Hunter, MD, discusses the current treatment landscape with JAK inhibitors in myelofibrosis.

Dr Costa on the Clinical Implications of the MASTER Trial in Multiple Myeloma

September 11th 2023

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPC

September 11th 2023

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

Dr Harpole on Perioperative Durvalumab Plus Chemotherapy in EGFR-Mutated NSCLC

September 11th 2023

David Harpole, MD, discusses findings from an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer.

Dr Jänne on Osimertinib Plus Platinum-Based Chemotherapy in EGFR-Mutant NSCLC

September 11th 2023

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS

September 9th 2023

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Dr Erba on the Role of Quizartinib in Newly Diagnosed FLT3-ITD+ AML

September 9th 2023

Harry Erba, MD, PhD, discusses the role of quizartinib for the treatment of newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Dr Mead on Unanswered Questions in the Treatment of MCL

September 8th 2023

Monica D. Mead, MD, discusses the importance of addressing unanswered questions in the treatment of patients with mantle cell lymphoma.

Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

September 8th 2023

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell Lymphoma

September 8th 2023

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Dr Lin on the Effect of Perioperative Treatment on Surgical Approaches in NSCLC

September 8th 2023

Jules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.

Dr. Li on the Potential For First-Line Triplet Therapy in HCC

September 8th 2023

Daneng Li, MD, discusses the investigation of triplet combination therapy for patients with hepatocellular carcinoma in the phase 1/2 Morpheus-Liver study.

Dr Hamilton on the Benefit Derived From Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 8th 2023

Erika P. Hamilton, MD, discusses the benefit seen with adjuvant ribociclib in patients with hormone receptor-positive,HER2-negative breast cancer.

Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.